Racial Differences in Risk of Prostate Cancer Associated With Metabolic Syndrome

Urology

Volumn 74, Issue 1, 2009, Pages 185-190

  Beebe Dimmer, Jennifer L ^a,b   Nock, Nora L ^c   Neslund Dudas, Christine ^d   Rundle, Andrew ^e   Bock, Cathryn H ^a,b   Tang, Deliang ^e   Jankowski, Michelle ^d   Rybicki, Benjamin A ^a,d  

^a WAYNE STATE UNIVERSITY   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d HENRY FORD HOSPITAL   (United States)

^e Mailman School of Public Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AFRICAN AMERICAN; ARTICLE; CANCER DIAGNOSIS; CANCER RISK; CASE CONTROL STUDY; CAUCASIAN; CLINICAL EVALUATION; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; OBESITY; POPULATION; PREVALENCE; PRIORITY JOURNAL; PROSTATE CANCER; RACE DIFFERENCE; UNITED STATES;

AFRICAN AMERICANS; CASE-CONTROL STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 67649213956     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2009.03.013     Document Type: Article

References (23)

1. Reaven G.M. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37 (1988) 1595-1607
2. Ford E.S., Giles W.H., and Dietz W.H. Prevalence of the metabolic syndrome among US adults-findings from the Third National Health and Nutrition Examination Survey. JAMA 287 (2002) 356-359
3. Day C. Metabolic syndrome, or what you will: definitions and epidemiology. Diab Vasc Dis Res 4 (2007) 32-38
4. Meigs J.B., Wilson P.W., Nathan D.M., et al. Prevalence and characteristics of the metabolic syndrome in the San Antonio Heart and Framingham Offspring Studies. Diabetes 52 (2003) 2160-2167
5. Ford E.S., Abbasi F., and Reaven G.M. Prevalence of insulin resistance and the metabolic syndrome with alternative definitions of impaired fasting glucose. Atherosclerosis 181 (2005) 143-148
6. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
7. Smith Jr. S.C., Clark L.T., Cooper R.S., et al. Discovering the full spectrum of cardiovascular disease: Minority Health Summit 2003: report of the Obesity, Metabolic Syndrome and Hypertension Writing Group. Circulation 111 (2005) e134-e139
8. Hammarsten J., and Hogstedt B. Clinical, haemodynamic, anthropometric, metabolic and insulin profile of men with high-stage and high-grade clinical prostate cancer. Blood Press 13 (2004) 47-55
9. Laukkanen J.A., Laaksonen D.E., Niskanen L., et al. Metabolic syndrome and the risk of prostate cancer in Finnish men: a population-based study. Cancer Epidemiol Biomarkers Prev 13 (2004) 1646-1650
10. Lund Haheim L., Wisloff T.F., Holme I., et al. Metabolic syndrome predicts prostate cancer in a cohort of middle-aged Norwegian men followed for 27 years. Am J Epidemiol 164 (2006) 769-774
11. Beebe-Dimmer J.L., Dunn R.L., Sarma A.V., et al. Features of the metabolic syndrome and prostate cancer in African-American men. Cancer 109 (2007) 875-881
12. Tuohimaa P., Tenkanen L., Syvala H., et al. Interaction of factors related to the metabolic syndrome and vitamin D on risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 16 (2007) 302-307
13. Hsing A.W., Sakoda L.C., and Chua Jr. S. Obesity, metabolic syndrome, and prostate cancer. Am J Clin Nutr 86 (2007) s843-s857
14. Barnard R.J., Aronson W.J., Tymchuk C.N., et al. Prostate cancer: another aspect of the insulin-resistance syndrome?. Obes Rev 3 (2002) 303-308
15. Smith G.D., Gunnell D., and Holly J. Cancer and insulin-like growth factor-I: a potential mechanism linking the environment with cancer risk. BMJ 321 (2000) 847-848
16. Tilg H., and Moschen A.R. Inflammatory mechanisms in the regulation of insulin resistance. Mol Med 14 (2008) 222-231
17. Tilg H., and Moschen A.R. Role of adiponectin and PBEF/visfatin as regulators of inflammation: involvement in obesity-associated diseases. Clin Sci (Lond) 114 (2008) 275-288
18. Tande A.J., Platz E.A., and Folsom A.R. The metabolic syndrome is associated with reduced risk of prostate cancer. Am J Epidemiol 164 (2006) 1094-1102
19. Ford E.S., Giles W.H., and Mokdad A.H. Increasing prevalence of the metabolic syndrome among U.S. Adults. Diab Care 27 (2004) 2444-2449
20. Ferdinand K.C., and Clark L.T. The epidemic of diabetes mellitus and the metabolic syndrome in African Americans. Rev Cardiovasc Med 5 suppl 3 (2004) S28-S33
21. Rybicki B.A., Neslund-Dudas C., Nock N.L., et al. Prostate cancer risk from occupational exposure to polycyclic aromatic hydrocarbons interacting with the GSTP1 Ile105Val polymorphism. Cancer Detect Prev 30 (2006) 412-422
22. Hall W.D., Clark L.T., Wenger N.K., et al. The metabolic syndrome in African Americans: a review. Ethn Dis 13 (2003) 414-428
23. Yood M.U., McCarthy B.D., Kempf J., et al. Racial differences in reaching target low-density lipoprotein goal among individuals treated with prescription statin therapy. Am Heart J 152 (2006) 777-784